PL3419595T3 - Stabilna ciekła formulacja gonadotropiny - Google Patents

Stabilna ciekła formulacja gonadotropiny

Info

Publication number
PL3419595T3
PL3419595T3 PL17707527T PL17707527T PL3419595T3 PL 3419595 T3 PL3419595 T3 PL 3419595T3 PL 17707527 T PL17707527 T PL 17707527T PL 17707527 T PL17707527 T PL 17707527T PL 3419595 T3 PL3419595 T3 PL 3419595T3
Authority
PL
Poland
Prior art keywords
stable liquid
liquid gonadotropin
gonadotropin formulation
formulation
stable
Prior art date
Application number
PL17707527T
Other languages
English (en)
Inventor
Helen Ulrika Sjögren
Charlotte HØJER-PEDERSEN
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3419595(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL3419595T3 publication Critical patent/PL3419595T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL17707527T 2016-02-24 2017-02-24 Stabilna ciekła formulacja gonadotropiny PL3419595T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603280.7A GB201603280D0 (en) 2016-02-24 2016-02-24 Stable liquid gonadotropin formulation
PCT/EP2017/054325 WO2017144659A1 (en) 2016-02-24 2017-02-24 Stable liquid gonadotropin formulation
EP17707527.2A EP3419595B1 (en) 2016-02-24 2017-02-24 Stable liquid gonadotropin formulation

Publications (1)

Publication Number Publication Date
PL3419595T3 true PL3419595T3 (pl) 2021-06-14

Family

ID=55806922

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20202758.7T PL3791860T3 (pl) 2016-02-24 2017-02-24 Stabilna ciekła formulacja gonadotropiny
PL17707527T PL3419595T3 (pl) 2016-02-24 2017-02-24 Stabilna ciekła formulacja gonadotropiny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20202758.7T PL3791860T3 (pl) 2016-02-24 2017-02-24 Stabilna ciekła formulacja gonadotropiny

Country Status (36)

Country Link
US (3) US10792334B2 (pl)
EP (3) EP3419595B1 (pl)
JP (3) JP6932710B2 (pl)
KR (1) KR20180114178A (pl)
CN (2) CN108883061B (pl)
AR (1) AR107782A1 (pl)
AU (2) AU2017222292B2 (pl)
BR (1) BR112018015166A2 (pl)
CA (1) CA3012759A1 (pl)
CL (1) CL2018001984A1 (pl)
CO (1) CO2018007810A2 (pl)
DK (2) DK3791860T3 (pl)
EA (1) EA036383B1 (pl)
ES (2) ES2862193T3 (pl)
FI (1) FI3791860T3 (pl)
GB (1) GB201603280D0 (pl)
HR (2) HRP20231477T1 (pl)
HU (2) HUE053492T2 (pl)
IL (1) IL260626B2 (pl)
JO (1) JOP20170046B1 (pl)
LT (2) LT3791860T (pl)
MA (2) MA43686B1 (pl)
MD (2) MD3419595T2 (pl)
MX (1) MX2018010201A (pl)
MY (1) MY193138A (pl)
PH (1) PH12018501688A1 (pl)
PL (2) PL3791860T3 (pl)
PT (2) PT3419595T (pl)
RS (2) RS61604B1 (pl)
SG (1) SG11201806140SA (pl)
SI (2) SI3419595T1 (pl)
TN (1) TN2018000284A1 (pl)
TW (1) TWI755377B (pl)
UA (1) UA123107C2 (pl)
WO (1) WO2017144659A1 (pl)
ZA (1) ZA201804944B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
WO2019164765A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
EP3860573A1 (en) * 2018-10-02 2021-08-11 InnoCore Technologies Holding B.V. Extended release formulations of human chorionic gonadotropin (hcg)
CN114404575A (zh) * 2020-12-07 2022-04-29 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2198299C (en) 1996-02-28 2000-05-02 Yuhei Abe Card holder-type balance display
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Fsh及びfsh変異体の製剤、製品及び方法
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP5551601B2 (ja) 2007-11-01 2014-07-16 メルク セローノ ソシエテ アノニム Lh液体調製物
SG10201604258YA (en) 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
WO2009098318A1 (en) 2008-02-08 2009-08-13 Biogenerix Ag Liquid formulation of fsh
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN102821782B (zh) * 2010-02-12 2015-07-15 印塔斯生物制药有限公司 促卵泡激素的液体配制品
WO2011108010A2 (en) 2010-03-05 2011-09-09 Intas Biopharmaceuticals Limited A thermostable liquid formulation of gonadotropins
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
CN105658201A (zh) * 2013-11-12 2016-06-08 卡迪拉保健有限公司 促性腺激素的制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Also Published As

Publication number Publication date
EP3791860A1 (en) 2021-03-17
MY193138A (en) 2022-09-26
JP6932710B2 (ja) 2021-09-08
JOP20170046B1 (ar) 2021-08-17
CN108883061B (zh) 2021-06-08
LT3419595T (lt) 2021-03-10
AU2017222292B2 (en) 2021-12-16
EP3791860B1 (en) 2023-10-11
CO2018007810A2 (es) 2018-10-22
US10792334B2 (en) 2020-10-06
JP2021191760A (ja) 2021-12-16
JP2023164573A (ja) 2023-11-10
ZA201804944B (en) 2023-02-22
MD3419595T2 (ro) 2021-06-30
HUE064432T2 (hu) 2024-03-28
IL260626B1 (en) 2023-04-01
IL260626A (pl) 2018-09-20
GB201603280D0 (en) 2016-04-13
EP3419595A1 (en) 2019-01-02
SI3791860T1 (sl) 2024-01-31
EP4257149A2 (en) 2023-10-11
MA43686A (fr) 2019-01-02
CN113398250B (zh) 2024-02-23
MX2018010201A (es) 2019-06-06
MD3791860T2 (ro) 2024-03-31
CL2018001984A1 (es) 2018-09-14
CN108883061A (zh) 2018-11-23
FI3791860T3 (fi) 2024-01-11
AR107782A1 (es) 2018-06-06
ES2966262T3 (es) 2024-04-19
RS64929B1 (sr) 2023-12-29
HUE053492T2 (hu) 2021-06-28
IL260626B2 (en) 2023-08-01
MA52595B1 (fr) 2023-12-29
AU2017222292A1 (en) 2018-07-26
US20230372447A1 (en) 2023-11-23
EP4257149A3 (en) 2023-12-20
SG11201806140SA (en) 2018-08-30
DK3791860T3 (da) 2023-12-18
ES2862193T3 (es) 2021-10-07
BR112018015166A2 (pt) 2018-12-18
AU2022200027A1 (en) 2022-02-03
HRP20231477T1 (hr) 2024-03-01
DK3419595T3 (da) 2021-03-29
CA3012759A1 (en) 2017-08-31
PT3791860T (pt) 2023-12-15
CN113398250A (zh) 2021-09-17
KR20180114178A (ko) 2018-10-17
SI3419595T1 (sl) 2021-04-30
MA52595A (fr) 2021-03-17
US11666635B2 (en) 2023-06-06
WO2017144659A1 (en) 2017-08-31
JP2019507153A (ja) 2019-03-14
PT3419595T (pt) 2021-03-29
EA201891905A1 (ru) 2019-02-28
PL3791860T3 (pl) 2024-03-18
EP3419595B1 (en) 2021-01-06
PH12018501688A1 (en) 2019-05-27
US20210236600A1 (en) 2021-08-05
EA036383B1 (ru) 2020-11-03
TN2018000284A1 (en) 2020-01-16
TWI755377B (zh) 2022-02-21
US20190060409A1 (en) 2019-02-28
HRP20210367T1 (hr) 2021-04-16
TW201733612A (zh) 2017-10-01
MA43686B1 (fr) 2021-03-31
LT3791860T (lt) 2023-12-11
RS61604B1 (sr) 2021-04-29
UA123107C2 (uk) 2021-02-17

Similar Documents

Publication Publication Date Title
HK1256195A1 (zh) 穩定的抗ifnar1配製品
GB201520014D0 (en) Liquid formulation
ZA201808476B (en) Stable liquid pharmaceutical preparation
ZA201901590B (en) Liquid pharmaceutical composition
GB201516729D0 (en) Liquid nicotine formulation
HUE054858T2 (hu) Folyékony gyógyszerészeti készítmény
ZA201804944B (en) Stable liquid gonadotropin formulation
SI3261676T1 (sl) Formulacije tekočega levotiroksina
ZA201806530B (en) Phosphaplatin liquid formulations
EP3305296A4 (en) AQUEOUS LIQUID FORMULATION
GB201720793D0 (en) Stable liquid formulations of pemetrexed
GB201505051D0 (en) Liquid formulation
GB201519512D0 (en) An edible liquid formulation